Therapeutic Area

Colorectal Cancer

Therapeutic area intelligence for Colorectal Cancer with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 9
Catalysts: 0
Companies: 3

Companies

Pfizer →

Roche →

Takeda →

Assets

Recent signals(9)

ClinicalJune 21, 2026

CircKPNA2 promotes colorectal cancer via RIN1-Ras pathway activation

CircKPNA2 is upregulated in colorectal cancer and activates the RIN1-Ras pathway, promoting tumor growth.

ClinicalJune 21, 2026

Novel KRAS(G12V)-targeting peptide shows potent activity against colorectal cancer cells

Peptide-1 demonstrated strong binding affinity to KRAS G12V and potent antiproliferative effects in colorectal cancer cell lines.

ClinicalJune 20, 2026

Lidocaine enhances efficacy of sorafenib and GW5074 in colorectal cancer cell lines

Lidocaine significantly enhances the antitumor effects of sorafenib and GW5074 in colorectal cancer cells, with varying responses across different cell lines.

ClinicalJune 19, 2026

Fruquintinib Study in Metastatic Colorectal Cancer Patients in Poland

A study is underway to evaluate the efficacy of fruquintinib in adults with metastatic colorectal cancer in Poland, focusing on progression-free survival and overall survival.

ClinicalJune 18, 2026

Phase III Trial of Atezolizumab with Chemotherapy for Metastatic Colorectal Cancer Initiated

The COMMIT study is evaluating the efficacy of atezolizumab in combination with chemotherapy and bevacizumab for metastatic colorectal cancer with DNA mismatch repair deficiency.

ClinicalJune 18, 2026

Cardiff Oncology and Pfizer assess onvansertib in metastatic colorectal cancer trial

A clinical trial is underway to evaluate onvansertib combined with standard therapies for first-line treatment of KRAS/NRAS-mutated metastatic colorectal cancer.

ClinicalJune 17, 2026

Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors

The study identifies age, neoadjuvant therapy, and tumor characteristics as risk factors for second primary cancer in colorectal cancer survivors.

ClinicalJune 17, 2026

Phase II Trial Compares FOLFOX8 and mFOLFOX6 in Metastatic Colorectal Cancer

A phase II trial is underway to compare the efficacy and safety of FOLFOX8 versus mFOLFOX6 with bevacizumab or cetuximab in patients with unresectable metastatic colorectal cancer.

ClinicalJune 16, 2026

Pfizer’s BRAFTOVI Regimen Nearly Doubles Progression-Free Survival in mCRC

The Phase 3 BREAKWATER study showed BRAFTOVI combined with cetuximab and FOLFIRI nearly doubled median progression-free survival to 15.2 months compared to 8.3 months with the comparator.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Colorectal Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.